On July 25, 2020, the Board of Directors of Kiniksa Pharmaceuticals, Ltd. approved an increase in the number of directors constituting the Board from eight to nine directors and the appointment of G. Bradley Cole to the Board to fill the vacancy created thereby, each effective as of July 27, 2020. Mr. Cole is a member of the Class II directors, joining Stephen R. Biggar and Barry D. Quart. Mr. Cole will also be a member of the Audit Committee of the Board, effective as of August 5, 2020. Mr. Cole will receive standard non-employee director compensation under the Company’s non-employee director compensation program under the sub-section of the Corporate Governance section of the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2020. In connection with his appointment to the Board, the Company has entered into its standard indemnification agreement for directors with Mr. Cole in substantially the form entered into by the Company with its other directors, which form of agreement was previously filed with the SEC on April 27, 2018.